Acotiamide

Acotiamide
Clinical data
Trade names	Acofide, others
Other names	YM-443, Z-338
Routes of; administration	By mouth
ATC code	A03FA10 (WHO) QA03FA10 (WHO);
Legal status
Legal status	JP: Rx-only;
Pharmacokinetic data
Protein binding	84.21–85.95%
Metabolism	UGT1A8 and 1A9 (major)
Elimination half-life	10.9–21.7 hours
Excretion	Feces (92.7%), urine (5.3%)
Identifiers
	IUPAC name N-{2-[bis(1-Methylethyl)amino]ethyl}-2-{[(2-hydroxy-4,5-dimethoxyphenyl)carbonyl]amino}-1,3-thiazole-4-carboxamide;
CAS Number	185106-16-5 ;
PubChem CID	5282338;
ChemSpider	4445505 ;
UNII	D42OWK5383;
KEGG	D08838 ;
ChEMBL	ChEMBL2107723 ;
CompTox Dashboard (EPA)	DTXSID40870163 ;
Chemical and physical data
Formula	C21H30N4O5S
Molar mass	450.55 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc1nc(C(=O)NCCN(C(C)C)C(C)C)cs1)c2cc(OC)c(OC)cc2O;
	InChI InChI=1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27) ; Key:TWHZNAUBXFZMCA-UHFFFAOYSA-N ;
	(what is this?) (verify)

Acotiamide, sold under the brand names Acofide,^[2]^[3] and Dyspevict is a medication manufactured and approved in Japan and Russia^[4] for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.^[5] It acts as an acetylcholinesterase inhibitor.